“…[9] Among the successful approaches, we would like to mention the g-amino acid RGD peptidomimetics containing a g-aminocyclopentane carboxylic acid or a 4aminoproline residue (14-membered ring), [10] the azabicyclic lactam RGD peptidomimetics (15-membered ring, with the scaffold mimicking a constrained dipeptide, e.g., ST1646), [11] and the b-amino acid RGD peptidomimetics, embodying b 3homoamino acids [12] (13-membered ring) or a cis-b-aminocyclopropane carboxylic acid (16-membered ring). [13] Up to now, a large number of linear or cyclic peptidic and peptidomimetic ligands have been developed, which are all related to the common recognition motif RGD [14] and a few potent ligands are presently in different stages of clinical trials for cancer therapy. Notwithstanding these recent achievements, the discovery of new ligands displaying high activity and selectivity together with an optimal pharmacological profile still remains a challenge.…”